Bioclin Diagnóstica

Executive Summary

Bioclin Diagnóstica (Quibasa-Bioclin) is a well-established Brazilian in-vitro diagnostics company founded in 1977, with a commercial-stage portfolio covering immunoassay and enzymatic kits for clinical laboratories. With 150–200 employees and a focus on quality certifications, the company serves the Brazilian diagnostic market and is positioned for regional expansion. While privately held and lacking recent funding rounds, Bioclin benefits from its long-standing reputation and continuous innovation. The company's growth trajectory hinges on capturing domestic demand for reliable diagnostic solutions and potential export opportunities in Latin America. Its strong local presence and broad product range provide a solid foundation, but limited visibility into financials and pipeline makes conviction moderate.

Upcoming Catalysts (preview)

• Q3 2026Launch of new immunoassay product line for infectious diseases70% success
• TBDStrategic partnership or distribution agreement for Latin American expansion50% success
• Q4 2026Receipt of international quality certification (e.g., ISO 13485 renewal)90% success